Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
(2025) European Journal of Cancer — Vol. 218, p. 115293 (2025)
